Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer
Thazin Nwe Aung(Yale University), David L. Rimm(Yale University), Niki Gavrielatou(National and Kapodistrian University of Athens), Ioannis Vathiotis(Yale Cancer Center), Arutha Kulasinghe(Translational Research Institute), James Monkman(The University of Queensland), Kurt A. Schalper(Yale University), Aileen I. Fernandez(Yale University), Jonathan Warrell(Yale University), Myrto Moutafi(University General Hospital Attikon), Katherine Bates(Yale University), Chin Wee Tan(The University of Queensland), Konstantinos Syrigos(National and Kapodistrian University of Athens), Ioannis P. Trontzas(Yale University), Ken O’ Byrne(Queensland University of Technology), Roy S. Herbst(Smilow Cancer Hospital)
Cited by 33
Related Papers
Lung Cancer
|New England Journal of Medicine|2008|2.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k